Global health financing is entering a period of structural recalibration. For journalists and policy analysts in countries like Bangladesh, where development trajectories remain closely intertwined with external support flows, the implications are profound. The longstanding aid architecture-built primarily on official development assistance (ODA) grants from a narrow circle of donor governments-has delivered measurable progress. Yet its overconcentration now represents a systemic vulnerability that demands a strategic reset.

As of 2023, grants accounted for between 75 percent and 95 percent of health-related assistance flowing into developing economies. This configuration made global health financing highly sensitive to fiscal and political shifts in a handful of donor capitals. While this model helped drive significant gains-including a 19 percent reduction in under-five mortality in low-income countries between 2011 and 2019-it has reached its structural limits.

The contraction now underway is not marginal. In 2024, total ODA fell by more than $15 billion. Estimates suggest an additional 9 to 17 percent decline in 2025, with cumulative risks of $40–$55 billion in development assistance by 2027. Bilateral ODA for health has declined even more sharply, falling 19 to 33 percent between 2023 and 2025-dropping below pre-pandemic baselines.

The policy consequences are visible. Of the 34 members of the Organisation for Economic Co-operation and Development Development Assistance Committee, 22 reduced aid budgets in 2024. The Joint United Nations Programme on HIV/AIDS has announced plans to halve its workforce and reduce its operational footprint from 75 to 36 countries following a sharp reduction in US contributions. Meanwhile, the World Health Organization has proposed a 14 percent cut to its core budget for 2026–27.

For least developed countries (LDCs), the contraction is especially acute. Bilateral ODA to LDCs fell by an estimated 13 to 25 percent in 2025 after a prior 3 percent drop in 2024. In sub-Saharan Africa, projected reductions range from 16 to 28 percent-effectively risking the loss of roughly one-quarter of total ODA within a single year. In the ten countries with the highest extreme poverty rates, the top five donors account for 85 percent of ODA inflows. The United States and the World Bank rank among the top two donors in eight of these states, underscoring the concentration risk embedded in the system.

This retrenchment reflects more than cyclical austerity. Between 2011 and 2024, health-related development assistance declined by approximately 24 percent as a share of global GDP, even accounting for a temporary pandemic surge. Moreover, the normative justification for health aid has evolved. Whereas earlier frameworks emphasized solidarity, human development, and poverty reduction, contemporary donor priorities increasingly emphasize economic self-interest, supply chain resilience, national security, and pandemic preparedness.

At the same time, the development finance ecosystem has grown more complex and multipolar. The BRICS+ grouping-particularly China, Russia, and India-has collectively disbursed more than $100 billion annually in development finance since 2022. Approximately 80 percent of this volume originates from China and is delivered primarily through loans and non-grant instruments.

The expanded BRICS+ bloc, now comprising 11 countries and accounting for roughly 27 percent of global GDP, is widely projected to overtake the G7 by mid-century. This shift will increasingly influence both the quantity and strategic orientation of global development flows. However, these newer providers tend to favor bilateral, project-based arrangements, infrastructure-heavy investments, and loan financing rather than grants. Their allocations often track geopolitical priorities, concentrating resources in strategically important corridors while leaving other fragile regions underserved.

Parallel to this geopolitical realignment, private equity, institutional investors, and impact funds are playing a more visible role in healthcare financing across Africa and Asia. Patient capital models, blended finance structures, and outcome-linked instruments are creating new pathways for mobilizing capital into health systems. Yet the investability of health projects varies significantly.

A detailed review of health security action plans in Côte d’Ivoire and Uganda demonstrates that only 25 to 30 percent of budgeted projects combine measurable health impact with predictable cash flows and structured revenue models. These tend to be infrastructure-driven assets-oncology centers, diagnostic facilities, specialized institutes-that can generate service-based revenues and potentially position host countries as regional hubs. In contrast, core public goods such as epidemiological surveillance, health workforce planning, and regulatory systems lack direct monetization pathways and remain reliant on grants or highly concessional finance.

According to estimates by the Boston Consulting Group, roughly 20 percent of national health expenditures-and potentially up to 30 percent of global health portfolios-could be structured to attract return-seeking capital. Realizing this potential requires reframing segments of health investment through an investment-grade lens: clarifying business models, modeling cash flows, defining risk-return parameters, and improving governance structures.

A central constraint is measurement architecture. Public donors traditionally evaluate health outcomes using indicators such as lives saved, morbidity reduction, or system resilience. Private investors, by contrast, require standardized metrics linking capital deployment to portfolio-level performance and internationally recognized sustainability benchmarks. One example is the “SDG Blue” rating system developed by Blue Like an Orange Sustainable Capital, which assigns investments a score from zero to ten based on alignment with specific Sustainable Development Goals (SDGs).

Scaling such frameworks could enhance transparency, comparability, and capital mobilization. However, financialization must not displace equity objectives. A bifurcated approach is required. Essential public goods and services for low-income populations-immunization programs, disease surveillance systems, rural primary care networks-must remain anchored in grant financing and concessional instruments. Infrastructure-heavy, revenue-generating health services-diagnostic chains, specialty hospitals, medical education institutes-can be structured to attract private and impact investors. Blended finance mechanisms can intermediate between these domains, aligning public, philanthropic, and commercial capital.

For Bangladesh, these global dynamics hold specific relevance. The country has demonstrated remarkable progress in maternal and child health, immunization coverage, and community health outreach-achievements historically supported by external financing partnerships. Yet as concessional flows tighten, Dhaka’s policymakers will need to deepen domestic resource mobilization, strengthen regulatory frameworks, and selectively structure bankable health infrastructure projects capable of crowding in diversified capital.

This transition will require technical sophistication. Governments must segment national health portfolios by risk profile, cash flow characteristics, and social externalities. Multilateral institutions should support transaction design, risk mitigation instruments, and performance measurement frameworks. Development partners must shift from volume-based disbursement metrics toward catalytic capital strategies.

Ultimately, the objective is resilience. A financing system overdependent on a narrow donor base is inherently fragile. A diversified architecture-combining grants, concessional loans, blended instruments, and structured private investment-offers greater shock absorption capacity.

The contraction in ODA should not be interpreted solely as retrenchment; it is also a forcing mechanism. It compels a reconsideration of incentives, instruments, and institutional design. By recognizing that impact and financial returns can, under appropriate conditions, be mutually reinforcing rather than mutually exclusive, policymakers can construct a more durable financing ecosystem.

Please follow Blitz on Google News Channel

The post Rethinking global health financing in an era of shifting power and shrinking aid appeared first on BLiTZ.

[Read More]

—–
Source: Weekly Blitz :: Writings